abrdn plc Takes $2.67 Million Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

abrdn plc purchased a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 363,161 shares of the company's stock, valued at approximately $2,666,000. abrdn plc owned approximately 0.26% of Vir Biotechnology as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of VIR. China Universal Asset Management Co. Ltd. grew its position in shares of Vir Biotechnology by 11.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 29,202 shares of the company's stock worth $214,000 after purchasing an additional 2,922 shares in the last quarter. KBC Group NV increased its stake in Vir Biotechnology by 136.5% during the 4th quarter. KBC Group NV now owns 8,970 shares of the company's stock worth $66,000 after acquiring an additional 5,177 shares during the period. Barclays PLC raised its holdings in Vir Biotechnology by 1.3% in the 3rd quarter. Barclays PLC now owns 550,186 shares of the company's stock valued at $4,121,000 after acquiring an additional 7,287 shares in the last quarter. State Street Corp lifted its position in shares of Vir Biotechnology by 10.4% during the 3rd quarter. State Street Corp now owns 5,625,533 shares of the company's stock valued at $42,135,000 after acquiring an additional 530,645 shares during the period. Finally, Quarry LP grew its holdings in shares of Vir Biotechnology by 901.8% during the 3rd quarter. Quarry LP now owns 17,000 shares of the company's stock worth $127,000 after purchasing an additional 15,303 shares in the last quarter. 65.32% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

VIR has been the subject of several recent analyst reports. JPMorgan Chase & Co. upped their price objective on shares of Vir Biotechnology from $10.00 to $14.00 and gave the stock a "neutral" rating in a research report on Thursday, January 9th. HC Wainwright reiterated a "buy" rating and set a $110.00 price target on shares of Vir Biotechnology in a research report on Friday, January 31st. Leerink Partners upped their target price on Vir Biotechnology from $18.00 to $20.00 and gave the stock an "outperform" rating in a research note on Monday, January 13th. Needham & Company LLC reaffirmed a "buy" rating and issued a $19.00 price objective on shares of Vir Biotechnology in a research note on Wednesday, November 20th. Finally, Morgan Stanley raised Vir Biotechnology from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $10.00 to $20.00 in a research note on Thursday, January 9th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $34.83.

Vir Biotechnology Trading Up 5.2 %

VIR traded up $0.47 on Thursday, reaching $9.58. The stock had a trading volume of 1,135,220 shares, compared to its average volume of 2,986,790. The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of -2.44 and a beta of 0.64. Vir Biotechnology, Inc. has a fifty-two week low of $6.56 and a fifty-two week high of $14.45. The firm has a 50-day moving average of $9.10 and a 200-day moving average of $8.49.

Insider Activity

In other news, Director Vicki L. Sato sold 10,960 shares of the firm's stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total transaction of $137,219.20. Following the completion of the transaction, the director now directly owns 1,312,391 shares in the company, valued at $16,431,135.32. This trade represents a 0.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 15.60% of the stock is currently owned by insiders.

Vir Biotechnology Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).